How to Get Dayvigo in Nebraska: Telehealth Access, Prescribers, and Pharmacy Options

What Is Dayvigo and Why Nebraska Patients Are Seeking It

Lemborexant is a dual orexin receptor antagonist (DORA) approved by the FDA in December 2019 for the treatment of insomnia disorder in adults [1]. It blocks orexin OX1R and OX2R receptors, suppressing the wake-promoting signaling of orexin neuropeptides rather than broadly depressing the central nervous system the way older benzodiazepines do [2].

The FDA label permits 5 mg at bedtime with an optional titration to 10 mg. Because it carries Schedule IV status under the Controlled Substances Act, prescribers must hold a valid DEA registration and, for telehealth prescribing, comply with the Ryan Haight Online Pharmacy Consumer Protection Act [3]. Nebraska follows federal scheduling without additional state restrictions on DORA-class medications.

Insomnia disorder affects roughly 10 to 30 percent of U.S. adults at any given time, according to data compiled by the American Academy of Sleep Medicine [4]. Nebraska-specific prevalence data from the CDC Behavioral Risk Factor Surveillance System places self-reported insufficient sleep among Nebraska adults at 32.4 percent, a figure that tracks closely with national averages [5]. Demand for prescription alternatives to zolpidem and eszopiclone has grown as clinicians and patients weigh the cognitive side-effect profiles of older agents against newer orexin-pathway drugs.

Clinical Evidence Supporting Lemborexant

The key SUNRISE-1 trial (N=1,006 adults with insomnia disorder) published in JAMA Network Open in 2019 found that lemborexant 5 mg and 10 mg both significantly reduced latency to persistent sleep compared with placebo at month one (least-squares mean difference versus placebo: 5 mg, minus 10.3 minutes; 10 mg, minus 14.1 minutes; both P<0.001) [6]. Subjective sleep onset latency improved by 14.5 minutes with the 10 mg dose versus 3.5 minutes with placebo. Sleep efficiency gains were sustained through the six-month endpoint.

The companion SUNRISE-2 trial (N=949) confirmed durable efficacy at 12 months, with patient-reported sleep onset latency continuing to improve relative to baseline and no statistically significant rebound insomnia signal on discontinuation [7]. This rebound finding matters clinically because Nebraska prescribers frequently ask patients to trial a DORA before initiating a benzodiazepine.

A 2020 network meta-analysis in the Lancet (N=154 randomized controlled trials, 44,089 participants) ranked lemborexant 10 mg among the top three agents for sleep onset and sleep maintenance outcomes with a favorable next-day function profile compared with triazolam and temazepam [8]. The American Academy of Sleep Medicine 2017 clinical practice guideline, updated with supplementary DORA guidance, states: "Clinicians should offer cognitive behavioral therapy for insomnia (CBT-I) as the initial treatment for chronic insomnia disorder" but explicitly lists pharmacotherapy, including orexin receptor antagonists, as evidence-based adjunct or primary therapy when CBT-I is unavailable or declined [9].

Next-day somnolence is the most frequently reported adverse event. In SUNRISE-1, somnolence occurred in 10 percent of patients on lemborexant 10 mg versus 1 percent on placebo. Prescribers counsel patients to allow at least seven to eight hours before planned awakening [6]. The FDA label includes a warning about complex sleep behaviors (sleepwalking, sleep-driving); Nebraska telehealth providers are required to document this counseling in the visit note [1].

Nebraska Telehealth Rules for Controlled Substance Prescribing

Nebraska permits telehealth prescribing of Schedule IV controlled substances under Nebraska Revised Statute 38-2137.01 and guidance from the Nebraska Department of Health and Human Services [10]. A synchronous audio-visual or audio-only encounter satisfies the prescribing standard when the provider holds both a Nebraska license and a federal DEA registration.

The DEA's March 2023 proposed rule on telemedicine prescribing of controlled substances initially created uncertainty, but the DEA extended a temporary exception through 2025 that allows providers with existing patient relationships to continue prescribing via telehealth without requiring an in-person visit for Schedule III and IV medications [11]. Lemborexant, as a Schedule IV drug, falls within this exception.

Practically, a Nebraska resident completes a video intake with a telehealth prescriber, the provider reviews sleep history and contraindications, and an electronic prescription is transmitted to a pharmacy of the patient's choice. Nebraska law allows electronic prescribing of Schedule IV controlled substances through PDMP-integrated platforms [12]. Providers access the Nebraska Prescription Drug Monitoring Program (PDMP) before every controlled substance prescription; this check is mandatory under Nebraska Administrative Code Title 172 [13].

A telehealth visit for insomnia evaluation at a direct-pay telehealth platform typically costs $75 to $150 in Nebraska. Several national platforms (HealthRX, Cerebral, Done, and others) hold Nebraska licenses and can see new patients without a prior in-person visit under the current DEA exception.

Who Can Prescribe Dayvigo in Nebraska

Nebraska operates under full independent practice authority for nurse practitioners, meaning NPs with an advanced practice registered nurse (APRN) license do not require physician oversight to prescribe Schedule IV controlled substances, provided they hold their own DEA number [14]. This makes Nebraska one of the easier states for telehealth APRN prescribing of lemborexant.

Physician assistants in Nebraska must maintain a collaborative practice agreement with a supervising physician to prescribe controlled substances [15]. The collaborative agreement does not need to be filed with the state, but it must be accessible for inspection. PAs practicing at telehealth platforms typically satisfy this requirement through their employer's medical director relationship.

MDs and DOs practicing in Nebraska face no additional restrictions beyond DEA registration and PDMP compliance. Foreign-licensed physicians who hold a Nebraska medical license and DEA registration may also prescribe.

Getting a Dayvigo Prescription: Step-by-Step Process for Nebraska Patients

Step 1. Select a licensed provider. Confirm the provider holds an active Nebraska license (verify at the Nebraska DHHS online license lookup) and an active DEA registration [16]. Telehealth platforms display prescriber credentials on their provider profiles.

Step 2. Complete the intake questionnaire. Most platforms request the Insomnia Severity Index (ISI) score, a brief sleep diary covering seven nights, current medications, and a review of contraindications including severe hepatic impairment (Child-Pugh C, for which lemborexant is not recommended per FDA label) [1].

Step 3. Attend the synchronous visit. The provider assesses whether CBT-I has been offered or attempted, discusses the orexin mechanism, and reviews the warning about complex sleep behaviors. No laboratory tests are required by FDA labeling before initiating lemborexant, though providers may order a hepatic function panel if clinical history suggests hepatic disease [1].

Step 4. Receive the electronic prescription. The prescription is transmitted to the pharmacy. Nebraska pharmacies receive Schedule IV e-prescriptions through DEA-compliant platforms.

Step 5. Fill at a Nebraska retail, mail-order, or 503A pharmacy. See the pharmacy section below.

Most Nebraska patients complete steps 1 through 4 on the same day and receive their medication within three to seven business days if using mail-order delivery.

Prior Authorization Requirements in Nebraska

Commercial insurance prior authorization for Dayvigo in Nebraska typically requires documentation of the following, drawn from representative Tier 3 PA criteria used by Blue Cross Blue Shield of Nebraska and Medica [17]:

• A diagnosis of chronic insomnia disorder (ICD-10 G47.00 or G47.09), present for at least one month
• A documented trial and failure or intolerance of at least two non-benzodiazepine receptor agonists (most commonly zolpidem 10 mg and eszopiclone 3 mg, each for at least two weeks)
• A provider attestation that the patient has been counseled on CBT-I

Nebraska Medicaid (Heritage Health) does not include lemborexant on its preferred drug list as of the 2025 formulary cycle [18]. Patients covered only by Medicaid should expect to pay out-of-pocket. The Eisai patient assistance program (Dayvigo Together) can reduce or eliminate cost for qualifying patients with income at or below 400 percent of the federal poverty level; enrollment requires a completed application submitted by the prescriber [19].

The average cash price for a 30-tablet supply of Dayvigo 5 mg at Nebraska retail pharmacies (Walgreens, Hy-Vee, Heartland Pharmacy) runs approximately $400 to $450 before coupons. GoodRx and SingleCare codes consistently bring this to $180 to $220 at participating Nebraska pharmacies.

Nebraska 503A Pharmacy Options for Lemborexant

Nebraska-licensed 503A compounding pharmacies may legally prepare lemborexant formulations for individual patients with a valid prescription [20]. Compounded lemborexant is not bioequivalent-tested against Dayvigo and is not FDA-approved, but it may offer lower cost or an alternative dose form (such as a sublingual preparation) when the commercial product is unavailable or cost-prohibitive.

To use a 503A pharmacy in Nebraska, the prescriber writes the prescription for "lemborexant [dose] [form] compounded" and designates a licensed Nebraska 503A pharmacy. The pharmacy must source the active pharmaceutical ingredient (API) from an FDA-registered API supplier and follow USP 795 standards for non-sterile compounding [21]. Patients should ask the pharmacy for a certificate of analysis confirming the API purity before the first fill.

Nebraska's Board of Pharmacy maintains a public list of licensed compounding pharmacies at its official website [22]. Telehealth platforms that work with Nebraska patients should be able to provide a short list of 503A partners on request.

Transferring an Existing Dayvigo Prescription to Nebraska

Federal DEA regulations allow a Schedule IV prescription to be transferred between pharmacies once, provided both pharmacies are registered with the DEA and the transfer is documented with the required notation on the original prescription record [23]. Nebraska pharmacies operating within the same chain (for example, one CVS to another CVS) may transfer Schedule IV prescriptions within that chain's internal system without the single-transfer limitation.

If a patient moves to Nebraska with an active Dayvigo prescription written by an out-of-state provider, the prescription remains valid at a Nebraska pharmacy for up to six months from the date written (for a Schedule IV), provided it has not been filled beyond the authorized refills [23]. The Nebraska pharmacy will access the PDMP to verify no concurrent Schedule IV controlled substance prescriptions exist.

Patients who want a Nebraska-licensed provider to take over ongoing management should schedule a telehealth transition visit. The new Nebraska provider reviews the prior prescription, obtains records from the out-of-state prescriber if possible, and issues a new Nebraska prescription. This visit does not require an in-person component under current DEA telehealth rules [11].

What to Expect After Starting Lemborexant

Most patients notice improvement in sleep onset within the first week at 5 mg. In SUNRISE-2, statistically significant improvement in subjective sleep onset latency appeared by week two at both doses [7]. If the 5 mg dose produces insufficient improvement after two weeks, the FDA label permits titration to 10 mg in patients without severe hepatic impairment [1].

Next-day residual sedation is the factor most likely to prompt a dose reduction. Patients are advised to measure their driving ability subjectively before operating a vehicle; the FDA label states that next-day driving impairment may persist even when patients feel alert [1]. Nebraska providers typically schedule a four-week follow-up visit (telehealth) to assess response and driving safety.

Long-term data from SUNRISE-2 show no clinically meaningful tolerance development over 12 months at either dose [7]. Abrupt discontinuation in that trial did not produce significant rebound insomnia or withdrawal symptoms, which contrasts with the profile of benzodiazepine receptor agonists such as zolpidem [7]. The American Academy of Sleep Medicine notes this discontinuation profile as a distinguishing feature of the orexin antagonist class [9].

Drug interactions are limited but relevant. Lemborexant is a CYP3A4 substrate. Co-administration with strong CYP3A4 inhibitors (fluconazole, clarithromycin, ritonavir) is not recommended; moderate CYP3A4 inhibitors (fluconazole at lower doses, diltiazem, erythromycin) require a dose reduction to 5 mg [1]. Nebraska prescribers using e-prescribing platforms with drug-interaction checking will receive alerts for these combinations automatically.

Monitoring and Follow-Up Protocol in Nebraska

No mandatory laboratory monitoring is required by the FDA label after initiation [1]. Nebraska telehealth providers generally follow this practice-level framework:

• Baseline: Review hepatic function history; obtain LFTs if history of hepatic disease. Confirm PDMP check. Document ISI score.
• Week 4: Telehealth follow-up. Reassess ISI score (a decrease of 8 points or more indicates clinical response [24]). Review next-day function and driving safety.
• Month 3: Re-evaluate ongoing need. Discuss whether a CBT-I referral is appropriate at this stage.
• Annually: Reassess diagnosis, continued indication, and whether deprescribing trials are appropriate.

Nebraska has no state-specific monitoring mandate for orexin receptor antagonists beyond the PDMP check at each prescribing event [13].

Cost Reduction Strategies Available in Nebraska

Nebraska patients have several options to reduce the out-of-pocket cost of Dayvigo:

The Eisai Dayvigo Together copay card reduces commercial insurance cost-share to as low as $30 for a 30-day supply for eligible commercially insured patients [19]. Uninsured patients may qualify for free medication through the Eisai patient assistance program. GoodRx codes at Hy-Vee and Bakers (Kroger affiliate) pharmacies in Nebraska have historically offered the lowest cash prices in the state. Mail-order pharmacy through commercial insurance typically reduces the 90-day supply cost compared with monthly retail fills.

A 503A compounding pharmacy may offer lower per-tablet pricing than the brand product, though patients should weigh the absence of bioequivalence data against the cost savings.